학술논문
Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)
Document Type
article
Author
Olga P. Nyssen; Pietro Pratesi; Miguel A. Spínola; Laimas Jonaitis; Ángeles Pérez-Aísa; Dino Vaira; Ilaria Maria Saracino; Matteo Pavoni; Giulia Fiorini; Bojan Tepes; Dmitry S. Bordin; Irina Voynovan; Ángel Lanas; Samuel J. Martínez-Domínguez; Enrique Alfaro; Luis Bujanda; Manuel Pabón-Carrasco; Luis Hernández; Antonio Gasbarrini; Juozas Kupcinskas; Frode Lerang; Sinead M. Smith; Oleksiy Gridnyev; Mārcis Leja; Theodore Rokkas; Ricardo Marcos-Pinto; Antonio Meštrović; Wojciech Marlicz; Vladimir Milivojevic; Halis Simsek; Lumir Kunovsky; Veronika Papp; Perminder S. Phull; Marino Venerito; Lyudmila Boyanova; Doron Boltin; Yaron Niv; Tamara Matysiak-Budnik; Michael Doulberis; Daniela Dobru; Vincent Lamy; Lisette G. Capelle; Emilija Nikolovska Trpchevska; Leticia Moreira; Anna Cano-Català; Pablo Parra; Francis Mégraud; Colm O’Morain; Guillermo J. Ortega; Javier P. Gisbert; on behalf of the Hp-EuReg Investigators
Source
Antibiotics, Vol 12, Iss 9, p 1427 (2023)
Subject
Language
English
ISSN
2079-6382
Abstract
The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the “most important” variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.